Beam Therapeutics Inc. (BEAM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 80.88M USD | Liabilities, Current |
| Cash and equivalents | 219.82M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 933.10M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $80.88M | $219.82M | $933.10M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $74.56M | $288.29M | $923.36M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $96.94M | $294.94M | $950.27M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $182.56M | $267.96M | $807.01M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $174.13M | $282.13M | $868.21M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $141.55M | $527.91M | $692.04M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $182.07M | $281.97M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $166.24M | $230.20M | $695.55M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $177.33M | $292.76M | $715.40M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $187.22M | $287.85M | $806.71M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $205.56M | $435.89M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $220.37M | $169.05M | $846.41M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $209.54M | $225.54M | $847.47M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $219.93M | $249.77M | $809.70M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $223.59M | $232.77M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $238.86M | $156.51M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $212.28M | $265.62M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $218.80M | $296.82M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $213.44M | $559.99M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $101.39M | $612.02M | $321.38M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $128.72M | $212.01M | $403.26M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $102.09M | $97.24M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $102.34M | $162.17M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $47.45M | $137.90M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $38.95M | $125.30M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $31.44M | $126.05M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $29.14M | $37.22M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $37.76M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $37.85M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $156.14M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |